BSN 315 HESI RN Specialty Pharmacology Exam V2 (2026/2027) Nightingale College | Grade A | 100% Correct
BSN 315 HESI RN SPECIALTY PHARMACOLOGY
EXAM V2
Latest Update | Questions & Answers | 100% Correct | Grade A - Nightingale
Alignment: Nightingale College BSN 315 Course Syllabus | HESI RN Specialty Exam Blueprint |
NCLEX-RN Test Plan | Nursing Pharmacology Standards (2026/2027 Edition).
Structure: 150 questions across 9 specialty sections covering pharmacokinetics, medication safety,
dosage calculations, and body-system pharmacology.
Cognitive Distribution: 20% recall, 50% application, 30% analysis (clinical reasoning, prioritization,
and medication calculations).
Format: 75% scenario-based (patient cases and clinical situations); 25% direct knowledge. Includes 5
integrated case studies with related questions.
Instructions: Select the single best answer for each question. Rationales cite Nightingale College
BSN 315 curriculum, HESI RN Specialty standards, and NCLEX-RN pharmacology references.
Section Topic Questions
1 Pharmacokinetics & Pharmacodynamics Q1 - Q20 (20)
2 Medication Safety & Administration Q21 - Q40 (20)
3 Dosage Calculations & Medication Math Q41 - Q60 (20)
4 Cardiovascular Pharmacology Q61 - Q80 (20)
5 Respiratory Pharmacology Q81 - Q95 (15)
6 Endocrine Pharmacology Q96 - Q110 (15)
7 Gastrointestinal & Renal Pharmacology Q111 - Q125 (15)
8 Neurological & Psychopharmacology Q126 - Q140 (15)
9 Anti-infective Pharmacology Q141 - Q150 (10)
TOTAL 150 Questions
Section 1: Pharmacokinetics & Pharmacodynamics
Page 1 | BSN 315 Pharmacology Exam V2 (2026/2027)
,BSN 315 HESI RN Specialty Pharmacology Exam V2 (2026/2027) Nightingale College | Grade A | 100% Correct
*Q1:* A nurse is preparing to administer an oral medication. Which phase of
pharmacokinetics describes the movement of the drug from the gastrointestinal tract into
the systemic circulation?
A. Distribution
B. Metabolism
C. Absorption *[CORRECT]*
D. Excretion
Correct Answer: C
Rationale: Absorption is the process by which a drug moves from its site of administration into
systemic circulation. Distribution refers to drug movement into body tissues, metabolism refers to
hepatic biotransformation, and excretion refers to drug elimination (typically renal). The BSN 315
curriculum emphasizes the ADME (Absorption, Distribution, Metabolism, Excretion) framework as
the foundation of pharmacokinetics.
*Q2:* A patient with hepatic cirrhosis is prescribed a medication that undergoes extensive
first-pass metabolism. The nurse anticipates that, compared with a patient with normal
liver function, the patient with cirrhosis will experience which effect?
A. Decreased bioavailability requiring higher doses
B. Increased bioavailability requiring lower doses *[CORRECT]*
C. No change in bioavailability
D. Faster hepatic elimination of the drug
Correct Answer: B
Rationale: First-pass metabolism occurs when drugs absorbed from the GI tract pass through the
liver via the portal vein before reaching systemic circulation. In cirrhosis, hepatocyte loss and
shunted blood flow reduce first-pass metabolism, increasing the fraction of active drug reaching
systemic circulation (increased bioavailability). Doses are typically reduced to prevent accumulation
and toxicity, a key BSN 315 concept.
*Q3:* A drug with a half-life of 12 hours is administered once daily at a maintenance dose.
Approximately how long will it take to reach steady-state plasma concentration without a
loading dose?
A. 24 hours
B. 36 hours
C. 48 hours
D. 60 to 72 hours *[CORRECT]*
Correct Answer: D
Rationale: Steady state is achieved after approximately 4 to 5 half-lives. With a half-life of 12 hours,
steady state is reached in 48 to 60 hours; clinical references commonly cite 60 to 72 hours as the
conservative estimate for full steady state. A loading dose can achieve therapeutic plasma levels
rapidly without waiting for steady state, which is critical for drugs with long half-lives such as
amiodarone or digoxin.
Page 2 | BSN 315 Pharmacology Exam V2 (2026/2027)
,BSN 315 HESI RN Specialty Pharmacology Exam V2 (2026/2027) Nightingale College | Grade A | 100% Correct
*Q4:* Which route of administration completely bypasses first-pass hepatic metabolism?
A. Oral (PO)
B. Sublingual
C. Rectal suppository
D. Intravenous (IV) *[CORRECT]*
Correct Answer: D
Rationale: Intravenous administration delivers the drug directly into systemic circulation,
completely bypassing first-pass hepatic metabolism, yielding 100% bioavailability. Sublingual
administration largely bypasses first-pass metabolism via venous drainage into the superior vena
cava. Rectal administration bypasses about 50% of first-pass metabolism. The oral route experiences
the greatest first-pass effect.
*Q5:* A patient taking warfarin (highly protein-bound) is started on
sulfamethoxazole-trimethoprim (also highly protein-bound). The nurse should monitor
closely for which effect?
A. Decreased therapeutic effect of warfarin
B. Increased risk of bleeding due to displacement of warfarin from albumin
*[CORRECT]*
C. Decreased metabolism of sulfamethoxazole
D. Increased renal excretion of warfarin
Correct Answer: B
Rationale: When two highly protein-bound drugs are administered concurrently, they compete for
binding sites on plasma albumin, displacing one drug and increasing the free (active) fraction.
Warfarin displacement elevates free warfarin levels, increasing INR and bleeding risk. This drug-drug
interaction is a classic BSN 315 pharmacology concept requiring close INR monitoring.
*Q6:* A patient receives a medication that is a competitive antagonist at the beta-1 receptor.
The nurse correctly understands that this medication will have which effect?
A. Produce a maximal physiologic response when given alone
B. Bind to the receptor without activating it, blocking the endogenous agonist
*[CORRECT]*
C. Increase the affinity of endogenous norepinephrine for the receptor
D. Irreversibly destroy the beta-1 receptor
Correct Answer: B
Rationale: A competitive antagonist binds to the same receptor site as the agonist without producing
a response, reversibly blocking agonist effects. Its effect can be overcome by increasing agonist
concentration (surmountable blockade). Antagonists possess receptor affinity but lack intrinsic
efficacy. Noncompetitive antagonists bind irreversibly or at a different allosteric site.
Page 3 | BSN 315 Pharmacology Exam V2 (2026/2027)
, BSN 315 HESI RN Specialty Pharmacology Exam V2 (2026/2027) Nightingale College | Grade A | 100% Correct
*Q7:* The therapeutic index (TI) of a medication is correctly calculated as:
A. ED50 divided by LD50
B. LD50 divided by ED50 *[CORRECT]*
C. TD50 multiplied by ED50
D. ED50 plus TD50
Correct Answer: B
Rationale: Therapeutic Index = LD50 / ED50, where LD50 is the lethal dose in 50% of the population
and ED50 is the effective dose in 50% of the population. A higher TI indicates a wider safety margin.
Drugs with a narrow TI, such as digoxin, warfarin, lithium, and phenytoin, require close plasma-level
monitoring per NCLEX-RN and HESI standards.
*Q8:* A patient taking phenytoin has a plasma level of 28 mcg/mL (therapeutic range 10 to
20 mcg/mL). The nurse anticipates observing which clinical finding?
A. Improved seizure control
B. Nystagmus and ataxia *[CORRECT]*
C. Hypotension and bradycardia
D. Hyperglycemia
Correct Answer: B
Rationale: Phenytoin toxicity manifests at plasma levels above 20 mcg/mL. Nystagmus appears early
(20 to 30 mcg/mL), followed by ataxia and slurred speech at 30 to 40 mcg/mL, and confusion or
seizures at levels above 40 mcg/mL. The therapeutic range of 10 to 20 mcg/mL reflects the drug's
narrow therapeutic index, mandating plasma monitoring per BSN 315.
*Q9:* The term bioavailability refers to:
A. The percentage of drug bound to plasma proteins
B. The rate at which a drug reaches its target organ
C. The fraction of the administered dose that reaches systemic circulation unchanged
*[CORRECT]*
D. The duration of drug effect at the receptor site
Correct Answer: C
Rationale: Bioavailability is the fraction (percentage) of the administered dose that reaches systemic
circulation in an active form. IV bioavailability is 100%. Oral bioavailability is reduced by incomplete
absorption and first-pass hepatic metabolism, varying by drug formulation and patient factors. These
concepts are foundational in BSN 315 pharmacokinetics.
Page 4 | BSN 315 Pharmacology Exam V2 (2026/2027)
BSN 315 HESI RN SPECIALTY PHARMACOLOGY
EXAM V2
Latest Update | Questions & Answers | 100% Correct | Grade A - Nightingale
Alignment: Nightingale College BSN 315 Course Syllabus | HESI RN Specialty Exam Blueprint |
NCLEX-RN Test Plan | Nursing Pharmacology Standards (2026/2027 Edition).
Structure: 150 questions across 9 specialty sections covering pharmacokinetics, medication safety,
dosage calculations, and body-system pharmacology.
Cognitive Distribution: 20% recall, 50% application, 30% analysis (clinical reasoning, prioritization,
and medication calculations).
Format: 75% scenario-based (patient cases and clinical situations); 25% direct knowledge. Includes 5
integrated case studies with related questions.
Instructions: Select the single best answer for each question. Rationales cite Nightingale College
BSN 315 curriculum, HESI RN Specialty standards, and NCLEX-RN pharmacology references.
Section Topic Questions
1 Pharmacokinetics & Pharmacodynamics Q1 - Q20 (20)
2 Medication Safety & Administration Q21 - Q40 (20)
3 Dosage Calculations & Medication Math Q41 - Q60 (20)
4 Cardiovascular Pharmacology Q61 - Q80 (20)
5 Respiratory Pharmacology Q81 - Q95 (15)
6 Endocrine Pharmacology Q96 - Q110 (15)
7 Gastrointestinal & Renal Pharmacology Q111 - Q125 (15)
8 Neurological & Psychopharmacology Q126 - Q140 (15)
9 Anti-infective Pharmacology Q141 - Q150 (10)
TOTAL 150 Questions
Section 1: Pharmacokinetics & Pharmacodynamics
Page 1 | BSN 315 Pharmacology Exam V2 (2026/2027)
,BSN 315 HESI RN Specialty Pharmacology Exam V2 (2026/2027) Nightingale College | Grade A | 100% Correct
*Q1:* A nurse is preparing to administer an oral medication. Which phase of
pharmacokinetics describes the movement of the drug from the gastrointestinal tract into
the systemic circulation?
A. Distribution
B. Metabolism
C. Absorption *[CORRECT]*
D. Excretion
Correct Answer: C
Rationale: Absorption is the process by which a drug moves from its site of administration into
systemic circulation. Distribution refers to drug movement into body tissues, metabolism refers to
hepatic biotransformation, and excretion refers to drug elimination (typically renal). The BSN 315
curriculum emphasizes the ADME (Absorption, Distribution, Metabolism, Excretion) framework as
the foundation of pharmacokinetics.
*Q2:* A patient with hepatic cirrhosis is prescribed a medication that undergoes extensive
first-pass metabolism. The nurse anticipates that, compared with a patient with normal
liver function, the patient with cirrhosis will experience which effect?
A. Decreased bioavailability requiring higher doses
B. Increased bioavailability requiring lower doses *[CORRECT]*
C. No change in bioavailability
D. Faster hepatic elimination of the drug
Correct Answer: B
Rationale: First-pass metabolism occurs when drugs absorbed from the GI tract pass through the
liver via the portal vein before reaching systemic circulation. In cirrhosis, hepatocyte loss and
shunted blood flow reduce first-pass metabolism, increasing the fraction of active drug reaching
systemic circulation (increased bioavailability). Doses are typically reduced to prevent accumulation
and toxicity, a key BSN 315 concept.
*Q3:* A drug with a half-life of 12 hours is administered once daily at a maintenance dose.
Approximately how long will it take to reach steady-state plasma concentration without a
loading dose?
A. 24 hours
B. 36 hours
C. 48 hours
D. 60 to 72 hours *[CORRECT]*
Correct Answer: D
Rationale: Steady state is achieved after approximately 4 to 5 half-lives. With a half-life of 12 hours,
steady state is reached in 48 to 60 hours; clinical references commonly cite 60 to 72 hours as the
conservative estimate for full steady state. A loading dose can achieve therapeutic plasma levels
rapidly without waiting for steady state, which is critical for drugs with long half-lives such as
amiodarone or digoxin.
Page 2 | BSN 315 Pharmacology Exam V2 (2026/2027)
,BSN 315 HESI RN Specialty Pharmacology Exam V2 (2026/2027) Nightingale College | Grade A | 100% Correct
*Q4:* Which route of administration completely bypasses first-pass hepatic metabolism?
A. Oral (PO)
B. Sublingual
C. Rectal suppository
D. Intravenous (IV) *[CORRECT]*
Correct Answer: D
Rationale: Intravenous administration delivers the drug directly into systemic circulation,
completely bypassing first-pass hepatic metabolism, yielding 100% bioavailability. Sublingual
administration largely bypasses first-pass metabolism via venous drainage into the superior vena
cava. Rectal administration bypasses about 50% of first-pass metabolism. The oral route experiences
the greatest first-pass effect.
*Q5:* A patient taking warfarin (highly protein-bound) is started on
sulfamethoxazole-trimethoprim (also highly protein-bound). The nurse should monitor
closely for which effect?
A. Decreased therapeutic effect of warfarin
B. Increased risk of bleeding due to displacement of warfarin from albumin
*[CORRECT]*
C. Decreased metabolism of sulfamethoxazole
D. Increased renal excretion of warfarin
Correct Answer: B
Rationale: When two highly protein-bound drugs are administered concurrently, they compete for
binding sites on plasma albumin, displacing one drug and increasing the free (active) fraction.
Warfarin displacement elevates free warfarin levels, increasing INR and bleeding risk. This drug-drug
interaction is a classic BSN 315 pharmacology concept requiring close INR monitoring.
*Q6:* A patient receives a medication that is a competitive antagonist at the beta-1 receptor.
The nurse correctly understands that this medication will have which effect?
A. Produce a maximal physiologic response when given alone
B. Bind to the receptor without activating it, blocking the endogenous agonist
*[CORRECT]*
C. Increase the affinity of endogenous norepinephrine for the receptor
D. Irreversibly destroy the beta-1 receptor
Correct Answer: B
Rationale: A competitive antagonist binds to the same receptor site as the agonist without producing
a response, reversibly blocking agonist effects. Its effect can be overcome by increasing agonist
concentration (surmountable blockade). Antagonists possess receptor affinity but lack intrinsic
efficacy. Noncompetitive antagonists bind irreversibly or at a different allosteric site.
Page 3 | BSN 315 Pharmacology Exam V2 (2026/2027)
, BSN 315 HESI RN Specialty Pharmacology Exam V2 (2026/2027) Nightingale College | Grade A | 100% Correct
*Q7:* The therapeutic index (TI) of a medication is correctly calculated as:
A. ED50 divided by LD50
B. LD50 divided by ED50 *[CORRECT]*
C. TD50 multiplied by ED50
D. ED50 plus TD50
Correct Answer: B
Rationale: Therapeutic Index = LD50 / ED50, where LD50 is the lethal dose in 50% of the population
and ED50 is the effective dose in 50% of the population. A higher TI indicates a wider safety margin.
Drugs with a narrow TI, such as digoxin, warfarin, lithium, and phenytoin, require close plasma-level
monitoring per NCLEX-RN and HESI standards.
*Q8:* A patient taking phenytoin has a plasma level of 28 mcg/mL (therapeutic range 10 to
20 mcg/mL). The nurse anticipates observing which clinical finding?
A. Improved seizure control
B. Nystagmus and ataxia *[CORRECT]*
C. Hypotension and bradycardia
D. Hyperglycemia
Correct Answer: B
Rationale: Phenytoin toxicity manifests at plasma levels above 20 mcg/mL. Nystagmus appears early
(20 to 30 mcg/mL), followed by ataxia and slurred speech at 30 to 40 mcg/mL, and confusion or
seizures at levels above 40 mcg/mL. The therapeutic range of 10 to 20 mcg/mL reflects the drug's
narrow therapeutic index, mandating plasma monitoring per BSN 315.
*Q9:* The term bioavailability refers to:
A. The percentage of drug bound to plasma proteins
B. The rate at which a drug reaches its target organ
C. The fraction of the administered dose that reaches systemic circulation unchanged
*[CORRECT]*
D. The duration of drug effect at the receptor site
Correct Answer: C
Rationale: Bioavailability is the fraction (percentage) of the administered dose that reaches systemic
circulation in an active form. IV bioavailability is 100%. Oral bioavailability is reduced by incomplete
absorption and first-pass hepatic metabolism, varying by drug formulation and patient factors. These
concepts are foundational in BSN 315 pharmacokinetics.
Page 4 | BSN 315 Pharmacology Exam V2 (2026/2027)
